Category | Lecanemab | ||||||
---|---|---|---|---|---|---|---|
Placebo | 2.5 mg/kg biweekly | 5 mg/kg monthly | 5 mg/kg biweekly | 10 mg/kg Monthly | 10 mg/kg biweekly | Total Lecanemab | |
(N = 238) | (N = 52) | (N = 48) | (N = 89) | (N = 246) | (N = 152) | (N = 587) | |
Age, median (range), years | 72 (50–89) | 71 (50–86) | 71 (55–84) | 72 (52–87) | 71 (53–90) | 73 (51–88) | 72 (50–90) |
Female, n (%) | 137 (58) | 26 (50) | 24 (50) | 48 (54) | 110 (45) | 64 (42) | 272 (46) |
CDR Global = 0.5 | 200 (84) | 44 (85) | 40 (83) | 77 (87) | 210 (85) | 133 (88) | 504 (86) |
Mild cognitive impairment | 154 (65) | 34 (65) | 33 (69) | 52 (58) | 166 (68) | 90 (59) | 375 (64) |
ApoE4 positive | 169 (71) | 38 (73) | 37 (77) | 81 (91) | 218 (89) | 46 (30) | 420 (72) |
Ongoing treatment with AChEIs and/or memantine | 128 (54) | 28 (54) | 25 (52) | 56 (63) | 131 (53) | 79 (52) | 319 (54) |
ADCOMS, mean (SD) | 0.37 (0.17) | 0.39 (0.20) | 0.40 (0.17) | 0.39 (0.16) | 0.37 (0.15) | 0.37 (0.15) | 0.38 (0.16) |
ADAS-Cog14, mean (SD)* | 22.6 (7.7) | 22.7 (8.1) | 22.9 (7.7) | 22.8 (6.7) | 21.9 (7.3) | 22.1 (7.7) | 22.2 (7.4) |
CDR-SB, mean (SD) | 2.9 (1.5) | 3.0 (1.6) | 2.9 (1.4) | 3.0 (1.3) | 2.9 (1.3) | 3.0 (1.4) | 3.0 (1.4) |
MMSE, mean (SD) | 26.0 (2.3) | 25.7 (2.5) | 25.3 (2.6) | 25.6 (2.3) | 25.7 (2.4) | 25.6 (2.4) | 25.6 (2.4) |
PET SUVr, mean (SD)† | 1.40 (0.16) | 1.41 (0.11) | 1.42 (0.17) | 1.40 (0.12) | 1.42 (0.18) | 1.37 (0.16) | 1.41 (0.16) |